Darmstadt, Germany – Sept 20, 2023
Advancing AI-Powered Drug Development in Oncology, Neurology, and Immunology
Merck, a global leader in science and technology, has announced strategic collaborations with BenevolentAI and Exscientia—two innovators in artificial intelligence (AI)-driven drug discovery. These alliances aim to fast-track the discovery and development of first-in-class and best-in-class drug candidates in oncology, neurology, and immunology, with the goal of increasing clinical success rates.
Harnessing AI for Breakthrough Medical Innovations
By integrating advanced AI technologies in drug design and discovery, Merck continues to push the envelope in research and development. The collaboration will utilize AI to enhance target identification, molecular design, and drug candidate optimization, helping streamline the R&D process.
“With the convergence of science, data, and AI, we’re determined to fast-track the development of truly innovative candidates, paving the way for breakthrough treatments,” said Danny Bar-Zohar, Global Head of Research & Development and Chief Medical Officer, Healthcare Business Sector at Merck.
Strategic Focus on Small Molecule Therapeutics
Initially, the partnerships will target three high-priority drug candidates, with opportunities to expand. The focus will be on AI-driven small molecule drug design aimed at optimizing candidates for preclinical and clinical development.
Financial Commitments and Growth Potential
Under the terms of the agreements, both BenevolentAI and Exscientia will receive upfront payments in the low double-digit million-dollar range. They are also eligible for milestone-based payments spanning discovery, development, regulatory, and commercialization phases. Additionally, the financial model includes tiered royalties based on net sales, aligning incentives among all parties. These strategic investments in AI research aim to boost Merck’s R&D productivity and long-term pipeline value.
Merck’s AI-Driven R&D Strategy
Artificial intelligence plays a central role in Merck’s long-term strategy to revolutionize drug discovery, clinical development, and lifecycle management. By embedding AI and advanced analytics throughout its R&D processes, Merck is focused on shortening timelines, improving efficiency, and delivering cutting-edge treatments to patients more quickly.
These collaborations underscore Merck’s leadership in biopharmaceutical innovation. As AI becomes an increasingly vital tool in drug development, Merck is staying ahead of the curve—harnessing technology to advance healthcare and improve lives.
About Merck KGaA, Darmstadt, Germany
Merck is a global science and technology powerhouse, innovating across the life sciences, healthcare, and electronics sectors. With over 64,000 employees worldwide, Merck is dedicated to pioneering medical breakthroughs, advancing drug development, and shaping the technological future. From cutting-edge treatments for complex conditions to enabling smarter, more connected devices, Merck delivers impactful solutions that promote global health and well-being. In 2022, the company reported €22.2 billion in sales across 66 countries.
More about this news
By
